Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E14.07 EPS (ttm)7.37 Insider Own0.40% Shs Outstand1.48B Perf Week2.29%
Market Cap153.79B Forward P/E9.96 EPS next Y10.41 Insider Trans-21.33% Shs Float1.47B Perf Month3.85%
Income12.10B PEG1.06 EPS next Q2.31 Inst Own86.40% Short Float3.91% Perf Quarter-1.74%
Sales24.89B P/S6.18 EPS this Y306.10% Inst Trans-0.04% Short Ratio4.90 Perf Half Y-2.25%
Book/sh10.25 P/B10.12 EPS next Y7.98% ROA39.40% Target Price119.08 Perf Year39.98%
Cash/sh6.83 P/C15.18 EPS next 5Y13.26% ROE82.80% 52W Range72.77 - 116.83 Perf YTD10.01%
Dividend- P/FCF12.54 EPS past 5Y39.10% ROI44.80% 52W High-12.09% Beta0.81
Dividend %- Quick Ratio2.80 Sales past 5Y28.80% Gross Margin84.80% 52W Low41.14% ATR2.20
Employees7000 Current Ratio3.10 Sales Q/Q134.40% Oper. Margin61.30% RSI (14)51.16 Volatility2.37% 2.05%
OptionableYes Debt/Eq0.80 EPS Q/Q373.90% Profit Margin48.60% Rel Volume0.87 Prev Close103.70
ShortableYes LT Debt/Eq0.77 EarningsApr 30 AMC Payout0.00% Avg Volume11.73M Price102.71
Recom2.00 SMA201.32% SMA500.96% SMA2001.27% Volume5,272,630 Change-0.95%
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Apr-27-15 12:17PM  Gilead Sciences: Still the One to Beat in Hepatitis-C at Barrons.com
10:39AM  S&P 500 hits new intraday high; Apple jumps more than 1.5% at CNBC
09:39AM  Bristol-Myers hepatatis C therapy with Sovaldi meets study goals at MarketWatch
08:30AM  Short Sellers Become More Wary of Big Biotech at 24/7 Wall St.
Apr-26-15 08:02AM  4 Top-Rated Drugmakers Reporting Earnings This Week at Investor's Business Daily
Apr-25-15 05:00PM  Bristol-Myers says hepatitis C drug combination succeeds in study Reuters
01:02PM  Trusty Horses; Tools, Pizza and Shoes: Jim Cramer's Best Blogs TheStreet
01:34AM  Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 at noodls
01:00AM  Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 Business Wire
Apr-24-15 07:00PM  Cramer's weird Apple Watch moment
06:32PM  Biz Break: The 2015 SV150: Apple in command, Wall Street has demands at San Jose Mercury News
06:28PM  Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
06:19PM  Humana (HUM), Gilead Sciences (GILD), McKesson Corporation (MCK) Among Sivik Globals Top Healthcare Stocks at Insider Monkey
05:36PM  AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
05:06PM  Bridgewater Increases Position in Microsoft Corporation
01:36PM  Midday Glance: Biotechnology companies
12:39PM  Gilead Sciences: Hepatitis-C Prescriptions Fall, So Does the Stock at Barrons.com
10:13AM  Merck: Hepatitis C Treatment Shows 95% Cure Rate at The Wall Street Journal
08:03AM  Hobbled Earnings, And Kissing Purgatory 'Good Buy' at Investor's Business Daily
07:55AM  EU regulators warn against combining hep C drugs with amiodarone Reuters
07:34AM  Merck says experimental Hepatitis C treatment shows 95% cure rate at MarketWatch
06:36AM  Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni
01:00AM  Merck oral hepatitis C regimen shows 95 pct cure rate
01:00AM  Mercks Hepatitis C Medicines May Challenge Gilead and AbbVie at Bloomberg
Apr-23-15 07:45PM  Biogen Earnings Preview: What To Look For at Investor's Business Daily
06:00PM  Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog
05:25PM  Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 at noodls
05:00PM  Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Business Wire
02:34PM  Gilead to Use a Give-Away Program in Georgia for Reducing Hepatitis C at The Wall Street Journal
11:46AM  AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed at Investor's Business Daily
10:45AM  Abbvie's CEO Gonzalez: We're Now In Pharma's 'Top Tier' at Forbes
03:06AM  AQR Capital More Than Doubles its Holdings in Gilead Sciences
01:00AM  Gileads Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease Business Wire
01:00AM  Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C Business Wire
Apr-22-15 08:01PM  Gilead Earnings Preview: What You Should Know at Investopedia
07:31PM  Forget Google: 5 Top Stocks With Earnings Thursday at Investor's Business Daily
12:20PM  Gilead Sciences (GILD) Stock Is the 'Chart of the Day' at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases
Apr-21-15 02:32PM  Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No at Barrons.com
01:19PM  Gilead's Stock Spikes on Possibility of Vertex Deal at The Wall Street Journal
12:57PM  Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
12:35PM  Time to take profits in biotech?
11:35AM  Will Amgen Earnings Shape Biotech for the Rest of 2015? at 24/7 Wall St.
09:23AM  Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition
09:09AM  Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
07:48AM  Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says at TheStreet
Apr-20-15 08:23PM  [Podcast] Earnings seasons busiest week: Watch these companies
05:17PM  Ignore These Risks to Gilead at Your Peril at Investopedia
11:14AM  Gilead Sciences: Why Nomura Sees Upside in Hepatitis C at Barrons.com
07:39AM  Banks look cheap, but biotechs frothy
Apr-19-15 02:50PM  Why This Trader Likes Gilead Better Than Biogen
Apr-18-15 11:20AM  Morningstar: Gilead Sciences To Grow Its Hepatitis C Market
Apr-17-15 06:39PM  Megamergers rarely mean megabucks for shareholders at Financial Times
02:15PM  This company doubled its Foster City office investment in 4 years at bizjournals.com
10:55AM  Gilead Sciences: Heading For a Hep-C Beat? at Barrons.com
Apr-16-15 06:14PM  AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
Apr-15-15 01:12PM  Will a New Vertex Drug for Cystic Fibrosis Become a Budget Buster? at The Wall Street Journal
Apr-14-15 10:38PM  How Gilead Plans to Keep Competitors in Check at Investopedia
05:48PM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
02:25PM  AbbVie: The Old & the New at Barrons.com
01:30PM  Five companies that may be looking to buy Ariad Pharmaceuticals at bizjournals.com
12:50PM  J&J cuts guidance as strong dollar hits sales at Financial Times
11:41AM  Two Biotech Buyout Candidates at Barrons.com
11:12AM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
11:09AM  IMS: US prescription drug spending jumped 13 pct. in 2014
09:46AM  Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts at TheStreet
09:30AM  J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Press Releases
06:00AM  Prescription drug spending jumps 13% to record $374 billion in 2014 at Los Angeles Times
04:58AM  Americans spent a record amount on medicine in 2014 at Fortune
12:10AM  Growth In Drug Spend Is Hitting A 13-Year High. Note To Pharma: Innovation Pays. at Forbes
12:00AM  U.S. Drug Spending Increases Most in 13 Years to $373.9 Billion
12:00AM  U.S. prescription drug spending rose 13 pct in 2014-IMS report
Apr-13-15 02:40PM  Q1 Earnings Season Ramps Up - Earnings Preview
02:37PM  5 Companies the crowd is betting on to beat Wall Street
02:04PM  Biotech: Making sense of the science at Financial Times
11:19AM  AbbVie Upgraded On $7.8 Billion Imbruvica Potential at Investor's Business Daily
08:35AM  Short Sellers Increase Their Bets Against Biotech Stocks at 24/7 Wall St.
07:40AM  How tech commercialization could pay off big for Johns Hopkins at bizjournals.com
Apr-12-15 01:00PM  Gilead combats wider distribution of cheap drugs from EM at Financial Times
Apr-10-15 05:00PM  Why Merck's Victory Is of Little Concern to Gilead at Investopedia
04:27PM  Stocks Up For Second Week As GE Soars at Barrons.com
01:10PM  Biotech Investors: Nomura Says To Watch These Dates
12:04PM  5 stocks to beat the street
10:10AM  Stock Market News for April 10, 2015 - Market News
10:10AM  Gilead: Little Hep C Competition, But What About Pricing? at Barrons.com
10:00AM  The Oprahs Of Biotech: People Who Can Go By First Name Only at Forbes
Apr-09-15 11:32PM  Natco Takes Patent Charge Honed in India to U.S. Market at Bloomberg
06:00PM  Three-Weeks-Tight Pattern Offers Second Chance To Buy Top Stock
01:10PM  Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
12:08AM  Gileads $1,000 Pill Is Hard for States to Swallow at The Wall Street Journal
Apr-08-15 10:58PM  Gilead's Little Tweak Could Produce Big Revenue at Investopedia
05:56PM  FDA Speeds Merck Reviews For Hep C's Sickest
05:16PM  Gilead's $1,000 Hep C Pill Is Hard for States to Swallow at The Wall Street Journal
03:26PM  Joel Greenblatts Magic Formula Worked During Q1 But Top Picks Undeperformed Mr. Market at Insider Monkey
02:53PM  Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
01:10PM  Opposing Views on Gilead Hepatitis C Presentation at 24/7 Wall St.
11:22AM  Latest Merck, AbbVie Data Not A Threat To Gilead: Citi at Barrons.com
11:00AM  Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog
10:08AM  Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie at TheStreet
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Option Exercise20.7470,0001,451,800235,168Apr 17 02:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Sale103.8470,0007,268,627165,168Apr 17 02:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Option Exercise19.095,00095,425150,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise80.651,00080,65046,439Apr 09 04:40 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Sale100.005,000500,000145,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale100.001,000100,00045,439Apr 09 04:40 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise14.50150,0002,175,3754,405,876Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise80.651,00080,65046,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise19.095,00095,425152,422Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale98.041,00098,04445,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale96.537,000675,715145,422Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Sale96.74150,00014,511,4634,255,876Apr 03 05:24 PM
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM